Therapeutic Asset Ratings

13,150 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Dasatinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (55)
Dasatinib Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (55)
Dasatinib Prostate Cancer	Medical University of South Carolina	P2	CCC (55)
Daunomycin Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (55)
Dexasone Solitary Osseous Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Dexrazoxane Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (55)
Disitamab Vedotin Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Disitamab Vedotin Rectal Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (55)
Docetaxel Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (55)
Domvanalimab Non-Small Cell Squamous Lung Carcinoma	Arcus Biosciences, Inc.	P2	CCC (55)
Donafenib Chemotherapy-Induced Toxicity	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (55)
Donafenib Digestive System Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (55)
Donanemab Cognitive Disorder	Eli Lilly and Company	P2	CCC (55)
Dostarlimab Pancreatic Neoplasm	Hopital Foch	P2	CCC (55)
Dpx-Survivac Relapsed/Refractory Diffuse Large B-Cell Lymphoma	ImmunoVaccine Technologies, Inc. (IMV Inc.)	P2	CCC (55)
Drf Multiple Sclerosis	Biogen	P2	CCC (55)
Dulaglutide Beta-Thalassemia Major	Ain Shams University	P2	CCC (55)
Durvalumab Lung Adenocarcinoma	University of British Columbia	P2	CCC (55)
Durvalumab Fallopian Tube Cancer	British Columbia Cancer Agency	P2	CCC (55)
Durvalumab Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (55)
(E)-3-(2-((5-(3-(Phenylsulfonamido)Phenyl)Pent-4-En-1-Yl)Oxy)Phenyl)Propanoic Acid Chemotherapy-Induced Neuropathy	Ono Pharmaceutical Co., Ltd.	P2	CCC (55)
Edotreotide Carcinoid Tumor	British Columbia Cancer Agency	P2	CCC (55)
Emicizumab Acquired Hemophilia A	University of Washington	P2	CCC (55)
Enasidenib Chronic Myelomonocytic Leukemia	Heinrich-Heine University, Duesseldorf	P2	CCC (55)
Enasidenib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	CCC (55)

Showing 2726 to 2750 of 13,150 assets

PreviousPage 110 of 526Next